Clinical Data Sanofi says drug for rare disease AATD tops standard care PharmaphorumAfter a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.Rare DiseaseRead full story pharminent May 19, 2026 (Last updated: May 19, 2026) Pharmaphorum After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: SCOTUS won’t hear pharma’s IRA complaintsNext: European study shows inequality in access to new medicines Related Stories Clinical Data Relay doubles the bar, outpacing Novartis with a 60% response in rare disease pharminent May 19, 2026 Clinical Data BioMarin suffers another blow to rare disease portfolio in Phase 3 flop pharminent May 19, 2026 Clinical Data UCB reports positive outcomes for bimekizumab in psoriatic arthritis pharminent May 19, 2026
